Vanta Bioscience Limited (VANTABIO.BO) Stock Competitors & Peer Comparison
See (VANTABIO.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VANTABIO.BO | ₹25.35 | +0.00% | 180.3M | 169.00 | ₹0.15 | N/A |
| BIOCON.BO | ₹421.60 | +0.06% | 578.9B | 150.12 | ₹2.82 | +0.12% |
| BIOCON.NS | ₹422.20 | +0.26% | 578.7B | 150.07 | ₹2.82 | +0.12% |
| ANTHEM.NS | ₹773.90 | +1.01% | 435.9B | 74.32 | ₹10.44 | N/A |
| ONESOURCE.NS | ₹1,579.30 | -2.20% | 179.7B | -243.83 | -₹6.43 | N/A |
| SYNGENE.BO | ₹441.00 | -0.55% | 175.2B | 55.55 | ₹7.85 | +0.29% |
| SYNGENE.NS | ₹440.20 | -0.72% | 175.2B | 55.26 | ₹7.89 | +0.29% |
| CONCORDBIO.NS | ₹1,294.70 | -3.21% | 137.9B | 53.31 | ₹24.72 | +0.81% |
| CONCORDBIO.BO | ₹1,295.00 | -3.35% | 137.9B | 53.20 | ₹24.79 | +0.81% |
| BLUEJET.NS | ₹520.50 | -0.19% | 89.3B | 29.23 | ₹17.61 | +0.23% |
Stock Comparison
VANTABIO.BO vs BIOCON.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, BIOCON.BO has a market cap of 578.9B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while BIOCON.BO trades at ₹421.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas BIOCON.BO's P/E ratio is 150.12. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to BIOCON.BO's ROE of +0.01%. Regarding short-term risk, VANTABIO.BO is more volatile compared to BIOCON.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check BIOCON.BO's competition here
VANTABIO.BO vs BIOCON.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, BIOCON.NS has a market cap of 578.7B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while BIOCON.NS trades at ₹422.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas BIOCON.NS's P/E ratio is 150.07. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to BIOCON.NS's ROE of +0.01%. Regarding short-term risk, VANTABIO.BO is more volatile compared to BIOCON.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check BIOCON.NS's competition here
VANTABIO.BO vs ANTHEM.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, ANTHEM.NS has a market cap of 435.9B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while ANTHEM.NS trades at ₹773.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas ANTHEM.NS's P/E ratio is 74.32. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to ANTHEM.NS's ROE of +0.22%. Regarding short-term risk, VANTABIO.BO is more volatile compared to ANTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check ANTHEM.NS's competition here
VANTABIO.BO vs ONESOURCE.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, ONESOURCE.NS has a market cap of 179.7B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while ONESOURCE.NS trades at ₹1,579.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas ONESOURCE.NS's P/E ratio is -243.83. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to ONESOURCE.NS's ROE of -0.01%. Regarding short-term risk, VANTABIO.BO is more volatile compared to ONESOURCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check ONESOURCE.NS's competition here
VANTABIO.BO vs SYNGENE.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, SYNGENE.BO has a market cap of 175.2B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while SYNGENE.BO trades at ₹441.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas SYNGENE.BO's P/E ratio is 55.55. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to SYNGENE.BO's ROE of +0.07%. Regarding short-term risk, VANTABIO.BO is more volatile compared to SYNGENE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check SYNGENE.BO's competition here
VANTABIO.BO vs SYNGENE.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, SYNGENE.NS has a market cap of 175.2B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while SYNGENE.NS trades at ₹440.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas SYNGENE.NS's P/E ratio is 55.26. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to SYNGENE.NS's ROE of +0.07%. Regarding short-term risk, VANTABIO.BO is more volatile compared to SYNGENE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check SYNGENE.NS's competition here
VANTABIO.BO vs CONCORDBIO.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, CONCORDBIO.NS has a market cap of 137.9B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while CONCORDBIO.NS trades at ₹1,294.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas CONCORDBIO.NS's P/E ratio is 53.31. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to CONCORDBIO.NS's ROE of +0.14%. Regarding short-term risk, VANTABIO.BO is more volatile compared to CONCORDBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check CONCORDBIO.NS's competition here
VANTABIO.BO vs CONCORDBIO.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, CONCORDBIO.BO has a market cap of 137.9B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while CONCORDBIO.BO trades at ₹1,295.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas CONCORDBIO.BO's P/E ratio is 53.20. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to CONCORDBIO.BO's ROE of +0.14%. Regarding short-term risk, VANTABIO.BO is more volatile compared to CONCORDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check CONCORDBIO.BO's competition here
VANTABIO.BO vs BLUEJET.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, BLUEJET.NS has a market cap of 89.3B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while BLUEJET.NS trades at ₹520.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas BLUEJET.NS's P/E ratio is 29.23. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to BLUEJET.NS's ROE of +0.20%. Regarding short-term risk, VANTABIO.BO is more volatile compared to BLUEJET.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check BLUEJET.NS's competition here
VANTABIO.BO vs BLUEJET.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, BLUEJET.BO has a market cap of 89.3B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while BLUEJET.BO trades at ₹519.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas BLUEJET.BO's P/E ratio is 36.07. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to BLUEJET.BO's ROE of +0.20%. Regarding short-term risk, VANTABIO.BO is more volatile compared to BLUEJET.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check BLUEJET.BO's competition here
VANTABIO.BO vs SUPRIYA.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, SUPRIYA.NS has a market cap of 77.3B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while SUPRIYA.NS trades at ₹952.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas SUPRIYA.NS's P/E ratio is 37.00. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to SUPRIYA.NS's ROE of +0.20%. Regarding short-term risk, VANTABIO.BO is more volatile compared to SUPRIYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check SUPRIYA.NS's competition here
VANTABIO.BO vs SUPRIYA.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, SUPRIYA.BO has a market cap of 77.3B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while SUPRIYA.BO trades at ₹952.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas SUPRIYA.BO's P/E ratio is 36.94. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to SUPRIYA.BO's ROE of +0.20%. Regarding short-term risk, VANTABIO.BO is more volatile compared to SUPRIYA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check SUPRIYA.BO's competition here
VANTABIO.BO vs ZOTA.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, ZOTA.NS has a market cap of 41.7B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while ZOTA.NS trades at ₹1,383.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas ZOTA.NS's P/E ratio is -58.77. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to ZOTA.NS's ROE of -0.21%. Regarding short-term risk, VANTABIO.BO is more volatile compared to ZOTA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check ZOTA.NS's competition here
VANTABIO.BO vs PANACEABIO.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, PANACEABIO.NS has a market cap of 33.9B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while PANACEABIO.NS trades at ₹556.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas PANACEABIO.NS's P/E ratio is -643.26. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to PANACEABIO.NS's ROE of -0.01%. Regarding short-term risk, VANTABIO.BO is more volatile compared to PANACEABIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check PANACEABIO.NS's competition here
VANTABIO.BO vs PANACEABIO.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, PANACEABIO.BO has a market cap of 33.8B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while PANACEABIO.BO trades at ₹554.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas PANACEABIO.BO's P/E ratio is -642.44. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to PANACEABIO.BO's ROE of -0.01%. Regarding short-term risk, VANTABIO.BO is more volatile compared to PANACEABIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check PANACEABIO.BO's competition here
VANTABIO.BO vs DCAL.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, DCAL.NS has a market cap of 27.1B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while DCAL.NS trades at ₹173.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas DCAL.NS's P/E ratio is 27.82. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to DCAL.NS's ROE of +0.02%. Regarding short-term risk, VANTABIO.BO is more volatile compared to DCAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check DCAL.NS's competition here
VANTABIO.BO vs DCAL.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, DCAL.BO has a market cap of 27.1B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while DCAL.BO trades at ₹173.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas DCAL.BO's P/E ratio is 27.82. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to DCAL.BO's ROE of +0.02%. Regarding short-term risk, VANTABIO.BO is more volatile compared to DCAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check DCAL.BO's competition here
VANTABIO.BO vs TITANBIO.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, TITANBIO.BO has a market cap of 17.3B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while TITANBIO.BO trades at ₹418.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas TITANBIO.BO's P/E ratio is 57.61. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to TITANBIO.BO's ROE of +0.18%. Regarding short-term risk, VANTABIO.BO is more volatile compared to TITANBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check TITANBIO.BO's competition here
VANTABIO.BO vs 3BBLACKBIO.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, 3BBLACKBIO.BO has a market cap of 10.1B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while 3BBLACKBIO.BO trades at ₹1,161.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas 3BBLACKBIO.BO's P/E ratio is 16.87. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to 3BBLACKBIO.BO's ROE of +0.20%. Regarding short-term risk, VANTABIO.BO is more volatile compared to 3BBLACKBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check 3BBLACKBIO.BO's competition here
VANTABIO.BO vs FERMENTA.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, FERMENTA.BO has a market cap of 10.1B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while FERMENTA.BO trades at ₹368.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas FERMENTA.BO's P/E ratio is 14.35. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to FERMENTA.BO's ROE of +0.19%. Regarding short-term risk, VANTABIO.BO is less volatile compared to FERMENTA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VANTABIO.BO.Check FERMENTA.BO's competition here
VANTABIO.BO vs KILPEST.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, KILPEST.BO has a market cap of 6.3B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while KILPEST.BO trades at ₹808.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas KILPEST.BO's P/E ratio is 18.32. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to KILPEST.BO's ROE of N/A. Regarding short-term risk, VANTABIO.BO is more volatile compared to KILPEST.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check KILPEST.BO's competition here
VANTABIO.BO vs TAKE.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, TAKE.NS has a market cap of 4.3B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while TAKE.NS trades at ₹28.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas TAKE.NS's P/E ratio is 102.31. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to TAKE.NS's ROE of +0.44%. Regarding short-term risk, VANTABIO.BO is more volatile compared to TAKE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check TAKE.NS's competition here
VANTABIO.BO vs TAKE.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, TAKE.BO has a market cap of 4.3B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while TAKE.BO trades at ₹29.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas TAKE.BO's P/E ratio is 103.21. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to TAKE.BO's ROE of +0.44%. Regarding short-term risk, VANTABIO.BO is more volatile compared to TAKE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check TAKE.BO's competition here
VANTABIO.BO vs HALEOSLABS.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, HALEOSLABS.NS has a market cap of 4.2B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while HALEOSLABS.NS trades at ₹1,379.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas HALEOSLABS.NS's P/E ratio is 24.02. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to HALEOSLABS.NS's ROE of +0.09%. Regarding short-term risk, VANTABIO.BO is more volatile compared to HALEOSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check HALEOSLABS.NS's competition here
VANTABIO.BO vs SMSLIFE.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, SMSLIFE.BO has a market cap of 4B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while SMSLIFE.BO trades at ₹1,478.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas SMSLIFE.BO's P/E ratio is 21.18. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to SMSLIFE.BO's ROE of +0.08%. Regarding short-term risk, VANTABIO.BO is more volatile compared to SMSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check SMSLIFE.BO's competition here
VANTABIO.BO vs HALEOSLABS.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, HALEOSLABS.BO has a market cap of 4B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while HALEOSLABS.BO trades at ₹1,478.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas HALEOSLABS.BO's P/E ratio is 22.90. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to HALEOSLABS.BO's ROE of +0.09%. Regarding short-term risk, VANTABIO.BO is more volatile compared to HALEOSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check HALEOSLABS.BO's competition here
VANTABIO.BO vs SMSLIFE.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, SMSLIFE.NS has a market cap of 3.9B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while SMSLIFE.NS trades at ₹1,299.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas SMSLIFE.NS's P/E ratio is 21.01. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to SMSLIFE.NS's ROE of +0.10%. Regarding short-term risk, VANTABIO.BO is more volatile compared to SMSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check SMSLIFE.NS's competition here
VANTABIO.BO vs LYKALABS.NS Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, LYKALABS.NS has a market cap of 2.4B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while LYKALABS.NS trades at ₹70.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas LYKALABS.NS's P/E ratio is -23.87. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to LYKALABS.NS's ROE of -0.10%. Regarding short-term risk, VANTABIO.BO is less volatile compared to LYKALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for VANTABIO.BO.Check LYKALABS.NS's competition here
VANTABIO.BO vs LYKALABS.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, LYKALABS.BO has a market cap of 2.4B. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while LYKALABS.BO trades at ₹69.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas LYKALABS.BO's P/E ratio is -28.96. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to LYKALABS.BO's ROE of -0.10%. Regarding short-term risk, VANTABIO.BO is more volatile compared to LYKALABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check LYKALABS.BO's competition here
VANTABIO.BO vs ALFAVIO.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, ALFAVIO.BO has a market cap of 274.6M. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while ALFAVIO.BO trades at ₹8.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas ALFAVIO.BO's P/E ratio is 217.75. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to ALFAVIO.BO's ROE of +0.00%. Regarding short-term risk, VANTABIO.BO is less volatile compared to ALFAVIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for VANTABIO.BO.Check ALFAVIO.BO's competition here
VANTABIO.BO vs TRABI.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, TRABI.BO has a market cap of 223.5M. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while TRABI.BO trades at ₹3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas TRABI.BO's P/E ratio is -13.41. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to TRABI.BO's ROE of -0.18%. Regarding short-term risk, VANTABIO.BO is more volatile compared to TRABI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check TRABI.BO's competition here
VANTABIO.BO vs SAMSRITA.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, SAMSRITA.BO has a market cap of 171.8M. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while SAMSRITA.BO trades at ₹11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas SAMSRITA.BO's P/E ratio is -8.59. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to SAMSRITA.BO's ROE of -0.64%. Regarding short-term risk, VANTABIO.BO is more volatile compared to SAMSRITA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check SAMSRITA.BO's competition here
VANTABIO.BO vs STARSOURCE.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, STARSOURCE.BO has a market cap of 144.4M. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while STARSOURCE.BO trades at ₹93.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas STARSOURCE.BO's P/E ratio is -1.22. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to STARSOURCE.BO's ROE of -0.93%. Regarding short-term risk, VANTABIO.BO is more volatile compared to STARSOURCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check STARSOURCE.BO's competition here
VANTABIO.BO vs GVBL.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, GVBL.BO has a market cap of 107.2M. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while GVBL.BO trades at ₹35.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas GVBL.BO's P/E ratio is 351.10. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to GVBL.BO's ROE of -0.01%. Regarding short-term risk, VANTABIO.BO is more volatile compared to GVBL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check GVBL.BO's competition here
VANTABIO.BO vs SERVOTEACH.BO Comparison June 2026
VANTABIO.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VANTABIO.BO stands at 180.3M. In comparison, SERVOTEACH.BO has a market cap of 0. Regarding current trading prices, VANTABIO.BO is priced at ₹25.35, while SERVOTEACH.BO trades at ₹20.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VANTABIO.BO currently has a P/E ratio of 169.00, whereas SERVOTEACH.BO's P/E ratio is N/A. In terms of profitability, VANTABIO.BO's ROE is -0.17%, compared to SERVOTEACH.BO's ROE of +0.00%. Regarding short-term risk, VANTABIO.BO is more volatile compared to SERVOTEACH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for VANTABIO.BO.Check SERVOTEACH.BO's competition here